Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has ...

For $950 million upfront, Sobi will gain ownership to pozdeutinurad, an oral URAT1 inhibitor that performed well in Phase II ...

The deal revolves around a drug Sobi claimed could become the “therapy of choice” for people whose gout symptoms persist ...

Most TikTok videos inaccurately portray gout flares as a personal choice that can be alleviated through a healthy diet, ...

Gout, a painful joint condition, is on the rise globally, affecting even younger individuals. This surge is linked to ageing ...

Samuela ‘Ofanoa, PhD, from the University of Auckland in New Zealand, and colleagues examined what types of gout content are on TikTok and assessed their association with user engagement. The analysis ...

Creators on the video platform consistently underplayed the extent to which the disease is caused by underlying factors and ...

Sobi has signed an agreement for the acquisition of US-based biotechnology company Arthrosi Therapeutics for $950m.

A new paper in Rheumatology Advances in Practice, published by Oxford University Press, indicates that TikTok videos about ...

Expands Sobi’s pipeline with a highly differentiated new Phase 3 asset in GoutAcquisition expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory Sobi® (STO:SOBI) has ...